CA2132348C - User activated iontophoretic device and method for using same - Google Patents
User activated iontophoretic device and method for using same Download PDFInfo
- Publication number
- CA2132348C CA2132348C CA002132348A CA2132348A CA2132348C CA 2132348 C CA2132348 C CA 2132348C CA 002132348 A CA002132348 A CA 002132348A CA 2132348 A CA2132348 A CA 2132348A CA 2132348 C CA2132348 C CA 2132348C
- Authority
- CA
- Canada
- Prior art keywords
- reservoir
- holding means
- medication
- patient
- electrical communication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 84
- 229940079593 drug Drugs 0.000 claims abstract description 81
- 239000003792 electrolyte Substances 0.000 claims abstract description 10
- 230000004913 activation Effects 0.000 claims description 23
- 230000004888 barrier function Effects 0.000 claims description 22
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 20
- 239000002550 vasoactive agent Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 16
- 238000004891 communication Methods 0.000 claims description 12
- 230000003444 anaesthetic effect Effects 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 229960004194 lidocaine Drugs 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 238000002483 medication Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000008213 purified water Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- 108010045937 Felypressin Proteins 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- NDNSIBYYUOEUSV-RSAXXLAASA-N (S)-ropivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C NDNSIBYYUOEUSV-RSAXXLAASA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- SFKQVVDKFKYTNA-DZCXQCEKSA-N felypressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](N)CSSC1 SFKQVVDKFKYTNA-DZCXQCEKSA-N 0.000 description 3
- 229960001527 felypressin Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229960003691 ropivacaine hydrochloride monohydrate Drugs 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960001813 ropivacaine hydrochloride Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Eye Examination Apparatus (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Prostheses (AREA)
- Water Treatment By Sorption (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9200820A SE9200820D0 (sv) | 1992-03-17 | 1992-03-17 | Package system containing vasoactive substances |
| SE9200820-0 | 1992-03-17 | ||
| US97228092A | 1992-11-05 | 1992-11-05 | |
| US07/972,280 | 1992-11-05 | ||
| PCT/US1993/002427 WO1993018727A1 (en) | 1992-03-17 | 1993-03-17 | User activated iontophoretic device and method for using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2132348A1 CA2132348A1 (en) | 1993-09-30 |
| CA2132348C true CA2132348C (en) | 2000-02-01 |
Family
ID=26661382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002132348A Expired - Fee Related CA2132348C (en) | 1992-03-17 | 1993-03-17 | User activated iontophoretic device and method for using same |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0586666B2 (enExample) |
| CN (1) | CN1079916A (enExample) |
| AT (1) | ATE153244T1 (enExample) |
| AU (1) | AU670434B2 (enExample) |
| CA (1) | CA2132348C (enExample) |
| DE (1) | DE69310844T3 (enExample) |
| DK (1) | DK0586666T4 (enExample) |
| ES (1) | ES2104141T5 (enExample) |
| HU (1) | HUT65957A (enExample) |
| IL (1) | IL105073A0 (enExample) |
| MX (1) | MX9301501A (enExample) |
| NO (1) | NO943459L (enExample) |
| WO (1) | WO1993018727A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3523334B2 (ja) | 1994-07-02 | 2004-04-26 | 久光製薬株式会社 | イオントフォレ−シス用プラスター構造体 |
| WO1997004835A1 (de) * | 1995-07-28 | 1997-02-13 | Novartis Ag | Transdermales system |
| DE69838485T2 (de) | 1997-10-09 | 2008-06-26 | Emory University | Verfahren und vorrichtung zur transdermalen verabreichung von lithium |
| US6374136B1 (en) * | 1997-12-22 | 2002-04-16 | Alza Corporation | Anhydrous drug reservoir for electrolytic transdermal delivery device |
| US6496727B1 (en) * | 2000-05-31 | 2002-12-17 | Becton, Dickinson And Company | Medicament-loaded transdermal reservoir and method for its formation |
| DE10148775B4 (de) * | 2001-10-02 | 2005-04-14 | Paul Mazac | Vorrichtung zur gesteigerten Einschleusung von therapeutischen Wirkstoffen, Medikamenten, Genen oder Plasmiden in menschliche oder tierische Tumorzellen und/oder kranke Zellen |
| MX2011002407A (es) * | 2008-09-05 | 2011-07-28 | Travanti Pharma Inc | Envase para la administracion iontoforetica de un farmaco. |
| US8329210B2 (en) * | 2008-09-23 | 2012-12-11 | Pharmapatch, Llc | Twin transdermal drug delivery patch |
| EP2393549B1 (en) * | 2008-12-30 | 2014-10-01 | NuPathe Inc. | Electronic control of drug delivery system |
| JP2017513686A (ja) * | 2014-04-23 | 2017-06-01 | セロス メディカル, エルエルシーSeros Medical, Llc | 真空アシスト薬剤送達デバイス及び方法 |
| CN109045454B (zh) * | 2018-10-25 | 2021-02-02 | 北京光捷扬基健康科技有限公司 | 一种中耳重复给药装置及人工耳蜗植入电极 |
| DE102019200558A1 (de) * | 2019-01-17 | 2020-07-23 | Lts Lohmann Therapie-Systeme Ag | Mikroarrayaufnahme |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3273269D1 (en) * | 1981-03-06 | 1986-10-23 | Medtronic Inc | Iontophoretic electrode |
| US5087240A (en) * | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4666441A (en) † | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| EP0249475A3 (en) † | 1986-06-13 | 1989-10-11 | Alza Corporation | Delayed percutaneous delivery |
| US5250022A (en) † | 1990-09-25 | 1993-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose |
| JPS63102768A (ja) † | 1986-10-20 | 1988-05-07 | 山之内製薬株式会社 | イオントフオレ−シス用の新規プラスタ−構造体 |
| IL86076A (en) * | 1988-04-14 | 1992-12-01 | Inventor S Funding Corp Ltd | Transdermal drug delivery device |
| US4927408A (en) † | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
| DE3903794A1 (de) † | 1989-02-09 | 1990-08-16 | Lohmann Therapie Syst Lts | Therapeutisches system zur transdermalen oder transmucosalen verabreichung von wirkstoffen und seine verwendung |
| DE3905050A1 (de) † | 1989-02-18 | 1990-08-30 | Lohmann Therapie Syst Lts | Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii) |
| DE3905051A1 (de) † | 1989-02-18 | 1990-08-30 | Lohmann Therapie Syst Lts | Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (i) |
| US4994023A (en) * | 1989-08-08 | 1991-02-19 | Wellinghoff Stephen T | Electrochemical drug release and article |
| US5320597A (en) † | 1991-02-08 | 1994-06-14 | Becton, Dickinson And Company | Device and method for renewing electrodes during iontophoresis |
| IT1244030B (it) * | 1989-12-21 | 1994-06-28 | Elan Corp Plc | Dispostitivo in due parti per la somministrazione controllata di un ingrediente |
| WO1991015261A1 (en) * | 1990-03-30 | 1991-10-17 | Medtronic, Inc. | Activity controlled electrotransport drug delivery device |
| WO1991015260A1 (en) * | 1990-03-30 | 1991-10-17 | Alza Corporation | Device and method for iontophoretic drug delivery |
| US5077033A (en) * | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| US5158537A (en) * | 1990-10-29 | 1992-10-27 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
-
1993
- 1993-03-16 IL IL105073A patent/IL105073A0/xx unknown
- 1993-03-16 HU HU9300748A patent/HUT65957A/hu active IP Right Revival
- 1993-03-17 DK DK93907552T patent/DK0586666T4/da active
- 1993-03-17 CA CA002132348A patent/CA2132348C/en not_active Expired - Fee Related
- 1993-03-17 WO PCT/US1993/002427 patent/WO1993018727A1/en not_active Ceased
- 1993-03-17 AU AU38116/93A patent/AU670434B2/en not_active Ceased
- 1993-03-17 MX MX9301501A patent/MX9301501A/es not_active IP Right Cessation
- 1993-03-17 EP EP93907552A patent/EP0586666B2/en not_active Expired - Lifetime
- 1993-03-17 ES ES93907552T patent/ES2104141T5/es not_active Expired - Lifetime
- 1993-03-17 DE DE69310844T patent/DE69310844T3/de not_active Expired - Fee Related
- 1993-03-17 CN CN93104559.2A patent/CN1079916A/zh active Pending
- 1993-03-17 AT AT93907552T patent/ATE153244T1/de not_active IP Right Cessation
-
1994
- 1994-09-16 NO NO943459A patent/NO943459L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0586666T4 (da) | 2001-06-18 |
| DK0586666T3 (da) | 1997-09-08 |
| EP0586666B2 (en) | 2001-02-07 |
| DE69310844D1 (de) | 1997-06-26 |
| HUT65957A (en) | 1994-08-29 |
| MX9301501A (es) | 1994-04-29 |
| ATE153244T1 (de) | 1997-06-15 |
| CN1079916A (zh) | 1993-12-29 |
| ES2104141T5 (es) | 2001-06-01 |
| AU670434B2 (en) | 1996-07-18 |
| NO943459D0 (no) | 1994-09-16 |
| AU3811693A (en) | 1993-10-21 |
| WO1993018727A1 (en) | 1993-09-30 |
| EP0586666A1 (en) | 1994-03-16 |
| DE69310844T2 (de) | 1997-11-13 |
| IL105073A0 (en) | 1993-07-08 |
| NO943459L (no) | 1994-11-15 |
| DE69310844T3 (de) | 2001-06-28 |
| HU9300748D0 (en) | 1993-05-28 |
| EP0586666A4 (enExample) | 1994-08-03 |
| ES2104141T3 (es) | 1997-10-01 |
| EP0586666B1 (en) | 1997-05-21 |
| CA2132348A1 (en) | 1993-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5817044A (en) | User activated iontophoertic device | |
| US5738647A (en) | User activated iontophoretic device and method for activating same | |
| US5797867A (en) | Iontophoretic drug delivery system, including method for activating same for attachment to patient | |
| US6374136B1 (en) | Anhydrous drug reservoir for electrolytic transdermal delivery device | |
| US5540669A (en) | Iontophoretic drug delivery system and method for using same | |
| US5160316A (en) | Iontophoretic drug delivery apparatus | |
| JPH0614980B2 (ja) | タンパク及びペプチド性薬物の経皮投与器具 | |
| CA2132348C (en) | User activated iontophoretic device and method for using same | |
| US5919156A (en) | Iontophoretic drug delivery system, including unit for dispensing patches | |
| US5954684A (en) | Iontophoretic drug delivery system and method for using same | |
| EP0934097B1 (en) | Iontophoretic drug delivery system, including method for activating same | |
| JP2003299743A (ja) | インスリン投与装置 | |
| JP3119488B2 (ja) | 水溶性ステロイド用イオントフォレーシスデバイス | |
| JP2542792C (enExample) | ||
| HK1032548B (en) | Anhydrous drug reservoir for electrolytic transdermal delivery device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |